2VT0
X-ray structure of a conjugate with conduritol-beta-epoxide of acid-beta-glucosidase overexpressed in cultured plant cells
2VT0 の概要
| エントリーDOI | 10.2210/pdb2vt0/pdb |
| 分子名称 | GLUCOSYLCERAMIDASE, alpha-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-3)]2-acetamido-2-deoxy-beta-D-glucopyranose, alpha-L-fucopyranose-(1-3)-[2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)]2-acetamido-2-deoxy-beta-D-glucopyranose, ... (6 entities in total) |
| 機能のキーワード | hydrolase, alternative initiation, sphingolipid metabolism, israel structural proteomics center, disease mutation, glucocerebrosidase, pharmaceutical, gaucher disease, lipid metabolism, glucosidase, glycosidase, polymorphism, glycoprotein, ispc, membrane, cerezyme, lysosome, structural genomics, alternative splicing |
| 由来する生物種 | HOMO SAPIENS (HUMAN) |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 115802.74 |
| 構造登録者 | Brumshtein, B.,Greenblatt, H.M.,Shaaltiel, Y.,Aviezer, D.,Silman, I.,Futerman, A.H.,Sussman, J.L. (登録日: 2008-05-03, 公開日: 2008-09-23, 最終更新日: 2024-10-23) |
| 主引用文献 | Kacher, Y.,Brumshtein, B.,Boldin-Adamsky, S.,Toker, L.,Shainskaya, A.,Silman, I.,Sussman, J.L.,Futerman, A.H. Acid Beta-Glucosidase: Insights from Structural Analysis and Relevance to Gaucher Disease Therapy. Biol.Chem., 389:1361-, 2008 Cited by PubMed Abstract: In mammalian cells, glucosylceramide (GlcCer), the simplest glycosphingolipid, is hydrolyzed by the lysosomal enzyme acid beta-glucosidase (GlcCerase). In the human metabolic disorder Gaucher disease, GlcCerase activity is significantly decreased owing to one of approximately 200 mutations in the GlcCerase gene. The most common therapy for Gaucher disease is enzyme replacement therapy (ERT), in which patients are given intravenous injections of recombinant human GlcCerase; the Genzyme product Cerezyme has been used clinically for more than 15 years and is administered to approximately 4000 patients worldwide. Here we review the crystal structure of Cerezyme and other recombinant forms of GlcCerase, as well as of their complexes with covalent and non-covalent inhibitors. We also discuss the stability of Cerezyme, which can be altered by modification of its N-glycan chains with possible implications for improved ERT in Gaucher disease. PubMed: 18783340DOI: 10.1515/BC.2008.163 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.15 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






